
CORRIGENDUM**Synthetic lethality screens point the way to new cancer drug targets***Asher Mullard**Nature Reviews Drug Discovery* **16**, 589–591 (2017)

The text has been changed to reflect that olaparib is the first, rather than the only, approved synthetic lethality-based drug.